Clinical Trial Update: Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and immunogenicity of a tetravalent chimeric dengue vaccine in healthy volunteers aged 1.5 to 45 years has completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever

Drugs mentioned

• Tetravalent chimeric dengue vaccine

Snippet

Sponsor: Takeda | Conditions: Healthy | Phase 2 | Status: COMPLETED | Results posted: 2018-03-27